PDL BioPharma, Inc. (PDLI)
Stock Price Chart
Key Info
| Market Cap | 360.07M |
| Revenue (ttm) | 85.10M |
| Net Income (ttm) | -108.81M |
| Shares Out | 113.95M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | 64.94 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $3.16 |
| Previous Close | $3.51 |
| Change ($) | -0.35 |
| Change (%) | -9.97% |
| Day's Open | 3.15 |
| Day's Range | 3.05 - 3.18 |
| Day's Volume | 1,240,283 |
| 52-Week Range | 1.71 - 3.52 |
More Stats
| Market Cap | 360.07M |
| Enterprise Value | 195.28M |
| Earnings Date (est) | Nov 11, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 113.95M |
| Float | 104.26M |
| EPS (basic) | -0.92 |
| EPS (diluted) | -0.93 |
| FCF / Share | 0.07 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 2.27% |
| Payout Ratio | n/a |
| Shares Short | 11.13M |
| Short Ratio | 9.73 |
| Short % of Float | 11.11% |
| Beta | 0.88 |
| PE Ratio | n/a |
| Forward PE | 64.94 |
| P/FCF Ratio | 44.12 |
| PS Ratio | 4.23 |
| PB Ratio | 0.69 |
| Revenue | 85.10M |
| Operating Income | -142.16M |
| Net Income | -108.81M |
| Free Cash Flow | 8.16M |
| Net Cash | 164.79M |
| Net Cash / Share | 1.45 |
| Gross Margin | 15.78% |
| Operating Margin | -167.05% |
| Profit Margin | -498.30% |
| FCF Margin | 9.59% |
| ROA | -3.19% |
| ROE | -15.08% |
| ROIC | -21.20% |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.76 | 198 | 320 | 244 | 590 | 581 | 456 | 381 | 362 | 345 |
| Revenue Growth | -72.36% | -38.1% | 31.01% | -58.62% | 1.59% | 27.39% | 19.79% | 5.2% | 4.95% | - |
| Gross Profit | 1.14 | 150 | 290 | 240 | 590 | 581 | 456 | 381 | 362 | 345 |
| Operating Income | -99.81 | -50.59 | 194 | 129 | 550 | 546 | 427 | 355 | 344 | 211 |
| Net Income | -70.41 | -68.86 | 111 | 63.61 | 333 | 322 | 265 | 212 | 199 | 91.87 |
| Shares Outstanding | 119 | 146 | 155 | 164 | 163 | 158 | 140 | 140 | 140 | 127 |
| Earnings Per Share | -0.59 | -0.47 | 0.71 | 0.39 | 2.03 | 1.86 | 1.66 | 1.45 | 1.15 | 0.54 |
| EPS Growth | - | - | 82.05% | -80.79% | 9.14% | 12.05% | 14.48% | 26.09% | 112.96% | - |
| Dividend Per Share | - | - | - | 0.10 | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 1.00 |
| Dividend Growth | - | - | - | -83.33% | 0% | 0% | 0% | 0% | -40% | - |
| Operating Cash Flow | -32.44 | -13.43 | 40.62 | 102 | 301 | 292 | 270 | 213 | 170 | 184 |
| Capital Expenditures | 76.81 | 53.45 | 106 | 13.06 | -71.60 | 21.31 | -241 | -0.05 | - | - |
| Free Cash Flow | 44.37 | 40.02 | 147 | 115 | 230 | 314 | 28.43 | 212 | 170 | 184 |
| Cash & Equivalents | 222 | 458 | 586 | 353 | 279 | 351 | 101 | 176 | 211 | 246 |
| Total Debt | 27.25 | 125 | 243 | 232 | 254 | 452 | 395 | 310 | 410 | 515 |
| Net Cash / Debt | 194 | 333 | 342 | 121 | 24.92 | -100 | -295 | -134 | -199 | -268 |
| Assets | 717 | 964 | 1,243 | 1,215 | 1,012 | 962 | 544 | 280 | 269 | 317 |
| Liabilities | 124 | 234 | 397 | 460 | 316 | 502 | 430 | 348 | 474 | 641 |
| Book Value | 593 | 730 | 846 | 751 | 696 | 460 | 113 | -68.12 | -204 | -324 |
Company Profile
Company Details
| Full Name | PDL BioPharma, Inc. |
| Country | United States |
| Employees | 109 |
| CEO | Dominique P. Monnet |
Stock Information
| Ticker Symbol | PDLI |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: PDLI |
| IPO Date | January 28, 1992 |
Description
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Medical Devices segment offers LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Strategic Positions segment develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.